Article Sidebar
Published:
Apr 9, 2020DOI:
10.4314/tjpr.v19i3.7Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Potentials of neuron-specific enolase as a biomarker for gastric cancer
Abstract
Purpose: To investigate the potentials of neuron-specific enolase (NSE) as a biomarker for gastric cancer (GC).
Methods: Gastric cancer (GC) patients (n = 412) who underwent gastrectomy were recruited over a 3- year period for this study. Their clinicopathological data such as age, sex, histological type, depth, tumor invasion, lymph node metastasis, and distant metastasis were analyzed. The patients were followed up for four years and the outcomes were also assessed. Histological changes in biopsies and levels of expression of NSE in biopsies and serum of patients were determined using immunohistochemical staining, western blotting and enzyme-linked immunosorbent assay (ELISA), respectively.
Results: Immunohistochemical staining showed that NSE was differentially expressed in the cytoplasm of GC cells. Histological changes in biopsies of patients in the overexpression group were not significantly different from those of patients in under-expression group (p > 0.05). In NSE overexpression group, the number of patients in early stage GC subgroup (n = 186, 86.10 %, T1) were significantly higher than that in advanced GC subgroup (n = 124, 62.20 % T2–T4) (p < 0.05). However, in NSE under-expression group, there were more patients in advanced GC subgroup (n = 72, 37.70 %) than in early GC subgroup (n = 30, 13.80 %) (p < 0.05). Patients in NSE overexpression group survived longer than those in NSE under-expression group (p < 0.05). The level of expression of NSE significantly decreased with increase in TNM stage (p < 0.05). There was no significant difference in serum NSE level between GC patients and healthy control (p > 0.05). The results of the correlation analysis indicated that NSE levels were positively associated with GC.
Conclusion: The results obtained in this study suggest that NSE could serve as a potential biomarker for GC.
Keywords: Biomarker, Gastric cancer, Neuron-specific enolase, Overexpression, TNM staging
